The BH3-only protein BID impairs the p38-mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice (2015) Hepatology, 62 (3), pp. 816-828. Loss of BID significantly delayed tumor development in two mouse models of FAH-mediated and HBsTg-driven hepatocarcinogenesis suggesting a tumor-promoting effect of BID. The degree of liver injury as well as basal and mitogen-stimulated hepatocyte proliferation was not modulated by BID. Moreover, there were no in vivo or in vitro evidence that BID was in the DNA damage response in hepatocytes and hepatoma cells. Our data revealed that chronic liver injury was associated with strong activation of the oxidative stress response.
Summary
Apoptosis is critical for maintaining tissue homeostasis and apoptosis evasion is considered as a hallmark of cancer. Increasing evidence however alos suggest that proapoptotic molecules can contribute to the development of cancer including liver cancer. The aim of this study was to further clarify the role of the proapoptotic BH3-only protein BID for chronic liver injury and hepatocarcinogenesis.
Loss of BID significantly delayed tumor development in two mouse models of FAH-mediated and HBsTg-driven hepatocarcinogenesis suggesting a tumor-promoting effect of BID. The degree of liver injury as well as basal and mitogen-stimulated hepatocyte proliferation was not modulated by BID. Moreover, there were no in vivo or in vitro evidence that BID was in the DNA damage response in hepatocytes and hepatoma cells. Our data revealed that chronic liver injury was associated with strong activation of the oxidative stress response.
BID impaired full activation of the MAPK p38 pathway following oxidative stress thereby facilitating the malignant transformation of hepatocytes. Conclusion: We provide evidence that the tumor-promoting function of BID in chronic liver injury is not related to enhanced proliferation or an impaired DNA damage response. In contast, ID promotes malignant transformation by suppressing p38 activity following oxidative stress.
Introduction
Liver cancer is the fifth most common cancer in men and the ninth in women worldwide (1) .
Among all cancer types, it is the second leading cause of cancer (1) and therefore a considerable health problem. Patients with hepatocellular carcinoma (HCC), the predominant form of liver cancer (2) , are confronted with limited therapeutic options (3) . In order to develop new innovative approaches to treat and to prevent tumor development in the liver, a better understanding of the underlying cellular mechanisms and molecular alterations is required.
Apoptosis, the best studied form of programmed cell death, is critical for maintaining tissue homeostasis and its deregulation is recognized as an important factor for tumorigenesis (4, 5) . The decision whether a cell should live or die is largely mediated by the BCL-2 family of anti-and proapoptotic proteins. The antiapoptotic proteins BCL-2, BCL-XL and MCL-1 are frequently overexpressed in HCC (6) (7) (8) (9) (10) (11) supporting the hypothesis that apoptosis resistance could contribute to HCC development and progression (5) . However, there is also evidence that increased apoptosis and proapoptotic molecules such as CD95 and BCL-2 like proteins promote hepatocarcinogenesis. In mouse models of ovary and liver cancer, loss of CD95 reduced cancer incidence and tumor size, demonstrating a growth-promoting role of CD95 during hepatocarcinogenesis (12) . In the murine model of DEN-mediated hepatocarcinogenesis, loss of PUMA or overexpression of BCL-2 delayed tumor development (13, 14) . In addition, hepatocyte-specific deletion of antiapoptotic MCL-1 enhanced proliferation and hepatocarcinogenesis in mice (15) . Based on these data, apoptosis can no longer be considered as a tightly sealed barrier against malignant disease, but as a mechanism that is also capable of causing tumor formation (16) .
The proapoptotic BCL-2 family member BID is an important mediator of apoptosis by connecting the receptor-and the mitochondria-mediated pathways of apoptosis (17) . Beyond its major function for apoptosis, BID has also been described to be critical for the onset of tumors. Treatment with the carcinogen diethylnitrosamine (DEN) significantly delayed tumor development, which was attributed to impaired hepatocyte proliferation (18) . Moreover, loss of BID delayed T-cell leukemogenesis in Atm -/-mice (19) .
The aim of this work was to further clarify the role of proapoptotic BID during hepatocarcinogenesis. Mice lacking an important enzyme of the tyrosine degradation pathway, the fumarylacetoacetate hydrolase (FAH), served as a murine HCC model. FAH deficiency leads to accumulation of toxic metabolites that cause liver damage (21, 22) .
Whereas treatment with the drug NTBC produces a healthy phenotype, reduced medication induces chronic liver injury and finally the development of HCC (23 Figure 1A , B). The cumulative tumor incidence and number were significantly lower in
whereas the mean maximum tumor size remained equal between both genotypes ( Figure   1D ). Since first liver tumors were detectable at six months of 2.5% NTBC treatment, threemonth-treated mice were subsequently used to analyze the molecular mechanisms that contribute to the delayed hepatocarcinogenesis in Fah -/-Bid -/-mice.
Induction of Oxidative Stress-Responsive Proteins Indicates Moderate Liver Damage at Early Stages of Chronic Liver Injury
First, we were interested to determine whether BID modulates the degree of chronic FAA- 
BID Is Dispensable for Hepatocyte Proliferation In Vivo
Several recent studies have shown that Bcl-2 like proteins do not only regulate apoptosis but also cell proliferation. Moreover, it has been shown that BID may impair hepatocyte proliferation during DEN-induced hepatocarcinogenesis (18) and progression through Sphase following DNA damage (28, 29) . To elucidate whether BID and phosphorylation of BID play a role in S-phase transition of hepatocytes, we first analyzed liver regeneration in Fig. 3 ). In line with the microarray results, protein levels of p21 and cyclin D1
were higher in mice with chronic liver injury, which was more prominent in Fah -/-mice. Hence, in agreement with the proliferation rate of hepatocytes an induction of cell cycle-associated genes was detectable during chronic liver injury, which was however similar between the two groups. Differences in proliferation may be low under basal conditions but more evident after mitogen stimulation. Therefore, chronically injured mice were also subjected to 2/3 PH. The proliferative capacity of chronically injured mice was strongly impaired after PH (Fig. 2D) , which is in line with our previous observation (23) . However, loss of BID had no significant influence on PH-induced hepatocyte proliferation in chronically injured Fah-deficient mice.
Taken together, these results indicate that BID does not significantly impair baseline hepatocyte proliferation during FAA-induced liver injury and following PH in wild type and
Fah-deficient mice. Moreover, phosphorylation of BID was dispensable for mitogenstimulated hepatocyte proliferation.
Delayed tumor development is accompanied with a reduced expression of Cancer-

Related Genes and Proteins in Chronically Injured BID-Deficient Mice
Microarray analysis was performed to identify molecular pathways that contribute to the tumor-promoting function of BID during hepatocarcinogenesis. 50 cancer-associated genes were identified whose expression was induced in tumor-prone mice compared with control mice (Fig. 4) (Fig. 5A ).
In line with the Fah model, reduced expression of BID had no significant impact on cell proliferation in Hepa1c1c7 cells, as determined by the crystal violet method (Fig. 5B) . To test whether impaired proliferation becomes evident in vivo, BID-silenced cells were injected into the flank of nude mice and monitored for tumor growth. As a result, tumors grew equally among all groups (Fig. 5C,D) . (Fig. 6C) .
DNA damaging agents stop cell cycle progression to enable repair of damaged DNA, usually by arresting cells in the G2/M phase. Therefore, cell cycle phase distribution was analyzed 8 hours after treatment (Fig. 6D) 
Loss of BID Delays Hepatocarcinogenesis by Reactivating the p38 Cellular Stress Response
Neither in vivo nor in vitro analyses revealed a major impact of BID on proliferation or the DNA damage response. Due to strong activation of the oxidative stress response in chronically injured mice, subsequent experiments were performed to clarify the role of BID during cellular stress. Environmental changes of the cell are sensed by the mitogen-activated protein kinase (MAPK) family, which mediates proliferation, differentiation, survival and/or apoptosis (32, 33) . In contrast to the extracellular signal-regulated kinase (ERK) MAPK pathway and the c-JUN NH2-terminal kinase (JNK) pathway (data not shown), the p38 MAPK, implicated in suppression of tumorigenesis (32) , showed a consistent genotypespecific protein expression pattern in vivo and in vitro (Fig. 7) .
Chronic liver injury was accompanied by a reduced activation and phosphorylation of p38, which was significantly stronger in tumor prone Fah -/-mice ( Figure 7A ). To investigate whether BID enters into direct interaction with p38 to suppress its phosphorylation, BID was immunoprecipitated from the protein lysate of chronically injured Fah -/-mice, where strongest p38 suppression was observed. Immunoprecipitation analysis however did not reveal a direct interaction between BID and p38 (Fig. 7B) .
To confirm the important relationship between BID and p38 during oxidative stress, a second mouse model was used, the HBV surface antigen transgenic mice (HBsTg) strain. HBsTg mice suffer from extensive oxidative DNA damage and develop chronic liver injury that subsequently proceeds to HCCs, mimicking the human disease (24) . After ten months, first liver tumors were detected in HBsTg mice and, in accordance with the Fah model, tumor development was significantly delayed in HBsTg Bid -/-mice (Fig. 7C) . Moreover, loss of BID resulted in increased levels of phosphorylated p38 compared with WT and HBsTg mice (Fig.   7D ). (Fig. 7E) . Collectively, in vivo and in vitro experiments suggest a suppressive role of BID on p38 activity in the context of oxidative stress. In the absence of BID, p38 activity is reactivated, facilitating a protective response to cellular stress.
Discussion
Apoptosis resistance is one of the hallmarks of cancer cells (5) . Consequently, proapoptotic molecules are supposed to induce apoptosis and to prevent tumor development. Contrary to this expectation, two previous studies with independent mouse models showed that loss of proapoptotic BID delays tumor development (18, 19) . In line with these findings, loss of BID significantly delayed tumor development following Fah -/--mediated and HBsTg-driven chronic injury. However, the underlying mechanisms how BID contributes to tumor formation are not fully understood, ranging from modulation of proliferation to involvement of the DNA damage response. Our attempt was therefore to examine more precisely which cellular mechanisms and signaling pathways are influenced by BID during chronic liver injury and hepatocarcinogenesis.
In DEN-treated Bid -/-mice, delayed hepatocarcinogenesis was attributed to reduced hepatocyte proliferation (18) . To test whether this correlation is also valid in the Fah model,
we analyzed basal and mitogen-stimulated proliferation in healthy mice and in mice with chronic liver injury. The basal proliferation rates were comparable among healthy and chronically injured mice and independent of BID. Accordingly, expression of cell cycle-related genes was similarly induced upon chronic liver injury without genotype specificity. Mice were also subjected to partial hepatectomy to stimulate proliferation and both genotypes showed similar proliferation rates. It was striking that Fah-mediated moderate injury substantially impaired hepatocyte proliferation, indicating that hepatocytes are disturbed to a degree that excludes proliferation as a possible compensatory mechanism to chronic liver damage.
Likewise, mitogen-stimulated proliferation was similar between Bid S61A/S78A knock-in mice and wild type controls and underlines that also BID phosphorylation has no impact on hepatocyte proliferation in vivo. Furthermore, shRNA-mediated silencing of BID in the hepatoma cell line Hep1c1c7 did not affect proliferation in vitro and tumor growth in vivo. Collectively, our data indicate that BID is not required for hepatocyte in our mouse models and for hepatoma cell proliferation.
The Fah model is characterized by accumulation of toxic metabolites, which are predicted to alkylate DNA and proteins, leading to excessive oxidative stress and genomic instability (34).
Due to the assigned role of BID in the DNA damage response (28, 29) , chronically injured Fah -/-and Fah -/-Bid -/-mice were analyzed for γ-H2AX, a common indicator of DNA double strand breaks. However, immunohistochemical stainings of chronically injured mice were negative for γ-H2AX. Hence, the role of BID in the DNA damage response was further delineated in vitro by treating Hepa1c1c7 cells with doxorubicin, cisplatin and H 2 O 2 . In our experimental setting, knockdown of BID had no effect on cell viability, cell cycle arrest or the responsiveness of p53 protein expression, which argues against an important role of BID for the DNA damage response in hepatocytes and hepatoma cells. In line with this finding, analysis of primary mouse embryonic fibroblasts showed that cell cycle arrest and apoptosis were indistinguishable between Bid -/-and wild type cells (35) . Collectively, our data indicat that BID is not involved in the DNA damage response of hepatocytes and hepatoma cells.
Our results show that the oxidative stress response is significantly activated in Fah-and are potent inducers of the NRF2-mediated stress response (37) (38) , which confirms the link between BID and p38 inhibition during oxidative stress. Activation of the p38 MAPK pathway inhibits proliferation or mediates apoptosis to protect cells from oxidative stress (32) .
Transformation of fibroblasts from p38α -/-mice with HRas12 was associated with increased ROS production, increased proliferation, increased ability to form colonies in soft agar, decreased apoptosis and accelerated subcutaneous tumor formation (39) . The fact that ectopic expression of p38α rescued these effects suggested that full activation of p38 suppresses tumorigenesis (40) . Dolado et al. proposed a model in which tumor cells uncouple ROS production from p38 activation to overcome the tumor-suppressive function of p38 (39) . We therefore hypothesize that BID overrides p38 activity by indirect interaction, leading to sustained ROS levels and consequently to malignant transformation (Fig. 8) . Loss of BID reactivates p38 activity thereby delaying tumor formation.
Together, we provide evidence in two independent mouse models that BID contributes to hepatocarcinogensis. The tumor-promoting function of BID was not attributed to enhanced proliferation or modulation of the DNA damage response, but promotes malignant transformation of hepatocytes by suppressing p38 activity during oxidative stress induced liver injury. stimulates other, yet unknown factors that suppress p38 activity. Inhibition of p38 activity can lead to malignant transformation. In the absence of BID, p38 is activated and can execute its protective function in the cell, which impedes or delays malignant transformation.
